Claim and evidence Close ×
Recursion and Exscientia announced on 8 August 2024 a definitive agreement to combine, under which Exscientia shareholders would receive 0.7729 shares of Recursion Class A common stock per Exscientia share, Recursion and Exscientia shareholders would own about 74% and 26% of the combined company, and closing was expected by early 2025. Copy claim link
Copy claim reference
Machine-checked, not reviewed by an editor Stated in source Supported
Supporting evidence: primary · 1 source
Provision Statement · provision ID co-recursion-exscientia-agreement-2024 Date 2024-08-08 · publication Records dated 2024 → Scope and limits Announced terms and an expected closing, subject to conditions stated in the release; completion is a separate record. The 74%/26% split is stated as based on the fixed exchange ratio and assuming no additional issuance by either company before closing; the closing expectation is stated as subject to the satisfaction or waiver of the closing conditions.
The evidence 03 primary source Supports the claim
Recursion and Exscientia Enter Definitive Agreement to Create A Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities ↗ Recursion Pharmaceuticals, Inc. and Exscientia plc (Exhibit 99.1 to Recursion Form 8-K) · 2024-08-08
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “Exscientia shareholders will receive 0.7729 shares of Recursion Class A common stock for each Exscientia ordinary share they own, with fractional shares paid in cash.” Location in source Transaction Details
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Recursion Pharmaceuticals, Inc. and Exscientia plc (Exhibit 99.1 to Recursion Form 8-K) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 ce47a6c63a6cc3399661915a5ec1786737ee6a5bf795795e865f1d6ebb556b22). Exhibit 99.1 to Form 8-K filed 2024-08-08, accession 0001193125-24-196505, as served by SEC EDGAR on 2026-10-30. Its wording can change; earlier wording is not authenticated. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Recursion Pharmaceuticals, Inc. and Exscientia plc (Exhibit 99.1 to Recursion Form 8-K), “Recursion and Exscientia Enter Definitive Agreement to Create A Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities”, 2024-08-08. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (25 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. primary source Supports the claim
Recursion and Exscientia Enter Definitive Agreement to Create A Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities ↗ Recursion Pharmaceuticals, Inc. and Exscientia plc (Exhibit 99.1 to Recursion Form 8-K) · 2024-08-08
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “Recursion shareholders will own approximately 74% and Exscientia shareholders will own approximately 26% of the combined company” Location in source Transaction Details
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Recursion Pharmaceuticals, Inc. and Exscientia plc (Exhibit 99.1 to Recursion Form 8-K) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 ce47a6c63a6cc3399661915a5ec1786737ee6a5bf795795e865f1d6ebb556b22). Exhibit 99.1 to Form 8-K filed 2024-08-08, accession 0001193125-24-196505, as served by SEC EDGAR on 2026-10-30. Its wording can change; earlier wording is not authenticated. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Recursion Pharmaceuticals, Inc. and Exscientia plc (Exhibit 99.1 to Recursion Form 8-K), “Recursion and Exscientia Enter Definitive Agreement to Create A Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities”, 2024-08-08. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (17 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. primary source Supports the claim
Recursion and Exscientia Enter Definitive Agreement to Create A Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities ↗ Recursion Pharmaceuticals, Inc. and Exscientia plc (Exhibit 99.1 to Recursion Form 8-K) · 2024-08-08
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “the transaction is expected to close by early 2025.” Location in source Transaction Details
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Recursion Pharmaceuticals, Inc. and Exscientia plc (Exhibit 99.1 to Recursion Form 8-K) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 ce47a6c63a6cc3399661915a5ec1786737ee6a5bf795795e865f1d6ebb556b22). Exhibit 99.1 to Form 8-K filed 2024-08-08, accession 0001193125-24-196505, as served by SEC EDGAR on 2026-10-30. Its wording can change; earlier wording is not authenticated. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Recursion Pharmaceuticals, Inc. and Exscientia plc (Exhibit 99.1 to Recursion Form 8-K), “Recursion and Exscientia Enter Definitive Agreement to Create A Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities”, 2024-08-08. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (9 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. Status and meaning Editorial status. Not reviewed by an editor . An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.
Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.
Date. Date of the joint press release. The record is dated by the text’s date of publication, which is the date of its announcement.
Record ID aib-co-recursion-exscientia-agreement-2024